BPC-157: research reference

Separate result and explanation. Activity under particular conditions does not define a specification for every material using the same name.

The peptide has been characterized in relation to VEGF receptor expression and FAK-paxillin signaling in cellular models. No specific receptor of its own has been identified.

The purity value is a product-label specification, not an assay result. A batch result can only be asserted from that batch’s certificate.

These names help identify the catalog entry. A descriptive label is not evidence of efficacy, and structural identity still requires appropriate documentation.

Repair peptide

Reconstitution: Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage: Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Personal protective equipment: Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

The systematic review searched publications through June 2024 and retrieved 544 articles dating from 1993. Screening retained 36 studies: 35 preclinical and one clinical. This distribution describes the evidence base better than a broad summary.

A 2011 in vitro study of rat tendon explants represents the cellular level. Its scope is isolated cellular behavior without circulation or an immune system; it concerns the peptide’s contact with cells rather than behavior in an organism (PMID 21030672). The level of measurement is central to interpreting its individual assays.

An animal experiment involved 32 Sprague-Dawley rats with Achilles tenotomy and repair, assigned to control, each peptide alone or their combination. At four weeks it assessed maximum load to failure, Bonar and Movin histological scores and type I and III collagen immunohistochemistry.

The mechanism review counts three human pilot studies: intra-articular exposure for chronic knee pain, interstitial cystitis, and intravenous safety and exposure. The sole nonpreclinical work retained by the systematic review was an uncontrolled retrospective study of twelve people with knee pain, seven of whom reported relief lasting more than six months. A 2026 sports-medicine review places BPC-157 among twelve peptides compared by mechanism, safety and regulatory status. Sources: PMID 40756949; PMID 21030672; PMID 42542926; PMID 40789979; PMID 41966639.

The 2026 biopharmaceutics review describes a formal preclinical ADME study in two species, providing three reported findings: plasma half-life below 30 minutes, linear kinetics and intramuscular bioavailability of 14–51% depending on species. The systematic review agrees on half-life and describes liver degradation and renal clearance.

These sources also record unusual stability in gastric juice and activity reported through oral, parenteral and topical routes in experimental models. They emphasize an unresolved disconnect: plasma residence lasts minutes, while reported preclinical effects extend from hours to days.

The references provide no albumin-binding or free-plasma-fraction data, biopharmaceutical classification, permeability characterization or formal excipient compatibility. No characterized pharmaceutical-grade formulation is available in this account. The human profile remains unestablished, resting on fewer than thirty subjects across three uncontrolled pilot studies without a standardized preparation. Sources: PMID 42198317; PMID 40756949; PMID 40789979.

BPC stands for body protection compound, the protein described and isolated in human gastric juice whose partial sequence this pentadecapeptide reproduces. The 2011 tendon-explant paper states that origin in its opening line; the 2025 review describes a synthetic pentadecapeptide originally isolated from gastric juice, and the 2026 biopharmaceutics review calls it derived from a gastric-protein fragment.

The fifteen declared residues, from initial glycine to terminal valine, represent that partial sequence rather than a de novo design. PL 14736 is another identifier.

The systematic review retrieved papers dating to 1993, and the 2026 review describes more than three decades of accumulated preclinical work. Development had not reached a validated clinical stage: as of April 2026, that review reported no approved formulation, validated regimen or completed phase II trial. It identifies missing basic pharmaceutical science, rather than an absence of described preclinical biological activity, as the barrier. Sources: PMID 21030672; PMID 40789979; PMID 42198317; PMID 40756949.

BPC-157 is the catalog’s only compound classified as a repair peptide, so there is no same-class peer group for a field-by-field table. A useful comparison with neighboring tissue-research compounds concerns size and target.

BPC-157 declares a fifteen-residue sequence. The name TB-500 alone does not establish a chain length or molecular mass for the other ingredient: the literature includes full-length thymosin beta-4 and fragments. That identity must be documented before comparing materials or interpreting the BPC-157 + TB-500 blend.

The four-week rat experiment is the only cited study measuring both peptides together, with the blend as the fourth group. The combination added nothing beyond either peptide alone; downstream convergence on shared pathways was offered as a hypothesis. Sources: PMID 41966639; PMID 42542926; PMID 40789979; PMID 21030672.

There is no completed phase II trial in the cited account. Human publications total fewer than thirty subjects in three uncontrolled pilot studies. The systematic review found no clinical safety data, although reviewed preclinical studies did not describe adverse effects in the organs examined. No specific receptor has been identified, and these references do not mechanistically explain the gap between minutes of plasma residence and hours-to-days of reported preclinical effects.

There is also tension between sources: reviews describe the accumulated preclinical evidence as robust, but in this bibliography’s only comparative experiment BPC-157 did not reach statistical significance for total histological scores, while the other peptide did. The sports-medicine review adds the potential mediating role of placebo and its amplification on social media. Sources: PMID 42198317; PMID 40789979; PMID 40756949; PMID 42542926; PMID 41966639.